Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern cooperative oncology group trial E2196

Stanley Zucker, Molin Wang, Joseph A. Sparano, William J. Gradishar, James N. Ingle, Nancy E. Davidson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.

Original languageEnglish (US)
Pages (from-to)525-529
Number of pages5
JournalClinical Breast Cancer
Volume6
Issue number6
DOIs
StatePublished - 2006

Fingerprint

Matrix Metalloproteinase 7
Matrix Metalloproteinase 9
Placebos
Breast Neoplasms
Matrix Metalloproteinase Inhibitors
Immunoenzyme Techniques
Multicenter Studies
marimastat
Clinical Trials
Drug Therapy
Survival

Keywords

  • Matrix metalloproteinase inhibitors
  • Phase III trials
  • Survival

ASJC Scopus subject areas

  • Cancer Research

Cite this

Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo : Eastern cooperative oncology group trial E2196. / Zucker, Stanley; Wang, Molin; Sparano, Joseph A.; Gradishar, William J.; Ingle, James N.; Davidson, Nancy E.

In: Clinical Breast Cancer, Vol. 6, No. 6, 2006, p. 525-529.

Research output: Contribution to journalArticle

Zucker, Stanley ; Wang, Molin ; Sparano, Joseph A. ; Gradishar, William J. ; Ingle, James N. ; Davidson, Nancy E. / Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo : Eastern cooperative oncology group trial E2196. In: Clinical Breast Cancer. 2006 ; Vol. 6, No. 6. pp. 525-529.
@article{af883862066147a4b6a535ae7e22936c,
title = "Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern cooperative oncology group trial E2196",
abstract = "Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.",
keywords = "Matrix metalloproteinase inhibitors, Phase III trials, Survival",
author = "Stanley Zucker and Molin Wang and Sparano, {Joseph A.} and Gradishar, {William J.} and Ingle, {James N.} and Davidson, {Nancy E.}",
year = "2006",
doi = "10.3816/CBC.2006.n.006",
language = "English (US)",
volume = "6",
pages = "525--529",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo

T2 - Eastern cooperative oncology group trial E2196

AU - Zucker, Stanley

AU - Wang, Molin

AU - Sparano, Joseph A.

AU - Gradishar, William J.

AU - Ingle, James N.

AU - Davidson, Nancy E.

PY - 2006

Y1 - 2006

N2 - Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.

AB - Background: The purpose of this study was to evaluate the prognostic and predictive utility of measuring plasma levels of matrix metalloproteinase (MMP)-7 and MMP-9 in patients with metastatic breast cancer (MBC) treated with the oral MMP inhibitor (MMPI) marimastat or a placebo. Patients and Methods: We measured plasma levels of MMP-7 and M MP-9 using an enzyme-linked immunoassay method in 140 evaluable patients with MBC enrolled on a multicenter clinical trial that compared the MMPI marimastat with placebo. Specimens were collected after completion of first-line chemotherapy in patients who had responding or stable disease and 3, 6, and 12 months after initiation of marimastat (10 mg orally twice daily) or placebo. Results: Baseline plasma MMP-7 and MMP-9 level s did not correlate with each other or with progression-free or overall survival. In addition, serial evaluation of plasma MMP-7 and MMP-9 levels revealed no significant changes over time in the marimastat or placebo groups or any correlation with trough plasma marimastat level. Conclusion: We conclude that measurement of plasma MMP-7 or MMP-9 levels, as performed in our trial, was not a useful prognostic or predictive factor in patients with MBC or in patients treated with an MMPI.

KW - Matrix metalloproteinase inhibitors

KW - Phase III trials

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33645642050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645642050&partnerID=8YFLogxK

U2 - 10.3816/CBC.2006.n.006

DO - 10.3816/CBC.2006.n.006

M3 - Article

C2 - 16595036

AN - SCOPUS:33645642050

VL - 6

SP - 525

EP - 529

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -